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lepharospasm is a focal dystonia of the 
Borbicularis oculi muscles. It may occur in isolation, or be associated with other 
dystonias such as Parkinsonism, dystonic cerebral 
palsy, and tardive phenomena. It is usually 
bilateral and is characterized by involuntary 
1closure of the eyelids .  It is usually progressive and 
could cause signicant disability. Blepharospasm 
often begins as excessive blinking, usually 
accompanied by feelings of dryness or irritation of 
the eyes which can progress into clonic and nally 
sustained tonic eyelid closure that can interfere 
2 
with daily activities. Blepharospasm can be 
disabling to the point of rendering a person 
3
functionally blind if left untreated.
The pathophysiology of blepharospasm is thought 
to involve a combination of loss of inhibition  
within the sensorimotor circuitry, disrupted 
sensorimotor integration, and maladaptive 
homeostatic plasticity. The interaction between 
cholinergic and dopaminergic transmission  
allows excessive unwanted movement resulting in 
the clinical manifestation of dystonia, abnormal 
3 
plasticity, and sensory dysfunction. Studies using 
transcranial magnetic stimulation (TMS) in 
4
dystonia show exaggerated cortical excitability,  
which supports the role of abnormal plasticity.
Symptoms are more likely to spread beyond the 
orbicularis oculi in patients who are women, have 
an older age at onset, or have a history of 
5
signicant head or facial trauma.
Men with primary blepharospasm tend to develop 
3symptoms at an earlier age.
The  risk of developing blepharospasm increases 
6with age .  One age-specic estimate showed a 
prevalence of 26.6 per 100,000 in people aged 
50–69, 31.9 per 100,000 in people aged 60–69, and 
7
74 per 100,000 in people over age 69 .  Possible risk 
factors for the development of primary adult-onset 
dystonia include family history of dystonia, 
postural tremor and prior signicant head or facial 
trauma, while hypertension and smoking 
5
cigaret tes  appear  to  be  protect ive .  For 
blepharospasm specically, prior history of eye 
disease is a possible risk factor, while drinking 
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BACKGROUND: Blepharospasm is a focal dystonia manifested by repetitive spasms of eyelid muscles which results in 
involuntary eye closure and often accompanied by sustained contractions of other facial and neck muscle. It is usually 
progressive and causes significant disability. It is commoner in females and prevalence increases with advancing age. 
Though distressing, it is successfully treated with botulinium toxin injection
CASE PRESENTATION: We present two cases of blepharospasm. Both patients had prior history of eye conditions requiring 
surgery. One had cataract extraction while the other had corneal transplant surgery prior to onset of spasm. The two 
conditions were successfully treated with botulinium toxin injection although the second patient had his dose of injection 
repeated and doubled before he responded to treatment.
CONCLUSION: Although blepharospasm is distressing and leads to functional blindness, it still has a high curative rate in its 
response to botulinium toxin injection even in African subjects.
INTRODUCTION
RBOTOX (XEOMIN ): CLOSTRIDIUM BOTULINIUM NEUROTOXIN 
TYPE A 150 KD INJECTION FOR BILATERAL ESSENTIAL BLEPHAROSPASM : 
PORT HARCOURT EXPERIENCE
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Adequate treatment of blepharospasm is necessary 
to maintain quality of life, avoid functional 
blindness, and prevent complications such as 
3
corneal abrasions and dermatochalasis. Botulinum 
toxin (BoNT) is the most commonly used therapy 
for blepharospasm.  It is produced by the bacteria 
Clostridium botulinum. It causes accid paralysis by 
blocking the release of acetylcholine at the 
9,10neuromuscular junction.  Intra muscularly , 2.5-
10 iu  is given every 3-6 months with some 
exceptions where it could last longer.The expected 
response rate to BoNT is very high. In a 
retrospective study, sustained benet  of about 2 
 years was seen in up to 92% of the patients .Usually 
patients that receive BoNT injections can expect 
long-term efcacy  of 3-6 months. Loss of 
11
effectiveness is rare, .
CASES 1. MS
A 65 year old male who presented with inability to 
open both eyes due to spastic contraction of the lids 
for more than 2 months. He reported that the 
condition followed bilateral cataract surgery. Any 
other history that we need to know? NO
Examination nding  showed he had spastic lid 
closure which is consistent with bilateral 
blepharospasm .
R 5IU of Botox (Xeomin Clostridium Botulinium 
neurotoxin type A 150 Kd) was injected into each 
lid and adjourning face at eight standard points 
following standard procedures. Two points each 
on the upper and lower lids, two points above the 
brow, a point each at the lateral canthus and the 
glabella.
The patient was reviewed 2 weeks later. He could 
now open the eyes freely with minimal residual 
spasm still observed. Three months post injection 
the patient was still doing well evidenced by ability 
to open the eyes, sustain it and with improved 
quality of life.
CASE 2. OG
75 years old man presented with inability to open 
both eyes as a result of sustained contraction of the 
lids for more than 2 years following bilateral 
corneal transplantation surgery.
A working diagnosis of bilateral essential 
blepharospasm was made and 5iu of Botox 
((XeominR Clostridium Botulinium neurotoxin 
type A 150 Kd)) injections administered to eight 
marked out points on the lids and adjourning face 
using standard procedure These included Two 
points each on the upper and lower lids, two points 
above the brow, a point each at the lateral canthus 
and the glabella.A dose of 5iu at each point making 
a total of 40iu. The patient was reviewed two weeks 
and one month later with no improvement in the 
condition. A repeat injection was given one month 
from the rst and patient was reviewed again  2 
weeks later with condition remaining the same. 
The dose was doubled six months later to 10iu per 
point and patient reviewed a week later with 
dramatic response.  
DISCUSSION
Blepharospasm is a focal dystonia of the 
orbicularis oculi muscles, .It is usually bilateral and 
is characterized by involuntary closure of the 
1eyelids just as in our patients.  It is usually 
progressive and  can cause signicant disability as 
seen in the cases presented.
T h e  r i s k  f a c t o r s  f o r  d e v e l o p m e n t  o f  
8
blepharospasm includes presence of eye diseases  
and/ or head or face trauma. This could be the 
trigger in our patients who respectively had 
cataract and also corneal pathology that could have 
necessitated a corneal transplant surgery. 
Furthermore surgical trauma itself could be the 
predisposing factor to the spasm since it involved 
5 an organ in the face/head region. Onset of 
symptoms were six month after the surgeries.
The  risk of developing blepharospasm increases 
6with age  which was the case in our patients. One 
age-specic estimate showed a prevalence  31.9 per 
100,000 in people aged 60–69, and 74 per 100,00 in 
7
people over age 69. This corresponds to the age 
group of our patients who were respectively 65 and 
75 years.
 The rst patient recovered after an initial dose of 
botox. This is in keeping with nding in a study 
which showed a 92% success rate following botox 
10injection. The second patient recovered after the 
initial dose was doubled. There was no recorded 
side effects in both patient even though studies 
have documented associated side effects with 
12botox. The advanced age of patients is also a risk 
factor for hypertension which incidentally is 
5protective for blepharospam. This could be a 
positive factor in preventing recurrence although 
our patients were not hypertensive.
 CONCLUSION
Eye diseases and/or surgery involving organ(s) in 
the head region could be  risk factors for 
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blepharospasm. However despite being a 
distressing condition, it is well managed with 
botulinium toxin injection although more cases 
would have been needed to substantiate this claim.
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